Association of British Clinical Diabetologists

Semaglutide Nationwide Audit

 
Home Live ABCD audits of new therapies and devices All ABCD nationwide audits Future audits of new therapies ABCD worldwide audits
     
semaglutide is more effective

Above: Clinical trials with semaglutide suggest that it is more effective than the other GLP-1 receptor agonists. It is now of interest for us to find out the extent to which the experience in clinical trials translates into the real world - click to see two slides about this

 
change in HbA1 by baseline - liraglutide audit

Above: In the ABCD nationwide liraglutide audit the higher the baseline HbA1c the bigger the fall In HbA1c. Will this also occur with semaglutide? If so we can expect very big falls in very poorly controlled patients - click to enlarge

 
HbA1c and body weight changes by diabetes duration

Above: In the ABCD liraglutide audit, the impact of liraglutide on fall in HbA1c reduced with increasing duration of diabetes. In clinical trials with semaglutide consistently reduced HbA1c and body weight across all diabetes durations. What will be the effect on duration of diabetes on response to semaglutide in real clinical use? click to see two slides about this

 
changes in HbA1c vs body weight by baseline 

Above: In previous ABCD audits of GLP1 receptor agonists, 60% of patients experienced reduction in both HbA1c and weight. In clinical trials with semaglutide this figure was about 80%. What percentage of patients will achieve reduction in both weight and HbA1c in real clinical practice? - click to see two slides about this

 
Heavier more poorly controlled patients received GLP1-RA in previous ABCD audits than in the clinical trials

Above: In real clinic practice in the UK, patients treated with exenatide or liraglutide had far worse glycaemic control and were much heavier than patients treated in clinical trials. Will the same be found in the semaglutide audit? If so will bigger falls in HbA1c and weight be seen in real clinical practice than in the clinical trials? - click to see two slides about this

ABCD nationwide semaglutide audit

About the ABCD nationwide semaglutide audit
This audit follows on from the success of the previous ABCD nationwide audits of GLP1 receptor agonists, SGLT2 inhibitors, insulin degludec, IDegLira and most recently the FreeStyle Libre. The clinical trials with semaglutide suggest that it is more effective than the other GLP-1 receptor agonists we have had to date and it is now of interest for us to find out the extent to which the experience in clinical trials translates into the real world. In the SUSTAIN 6 trial semaglutide seemed to have a bigger impact on cardiovascular outcomes than previously studied diabetes medications which may increase its usage in view of the consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) suggesting that agents with proven cardiovascular benefit should be used more readily in type 2 diabetes patients with established atherosclerotic cardiovascular disease. The audit will be hosted on a tool very similar to that used in the liraglutide audit, the degludec audit and the IDegLira audit so the many contributors taking part in those audits will find it particularly easy. The audit launched in January 2019 and has a number of objectives.

Collect data on-line or via paper forms
The semaglutide on-line audit tool is so easy to use that live data entry in clinic is a real option to be considered. Otherwise to facilitate data collection during clinics there are two paper forms which exactly match the data that can be entered into the audit tool. You can download and print these forms locally
.

To download the forms to printout for use, use the following links:

Download first visit data entry form
Download follow up visit data entry form

Non ABCD members
Non ABCD members are welcome to take part in the audit and will be given access to the on-line audit tool when they register for the audit.

Analyse your own data
The tool will allow you to analyse the data of your own patients for your own local interest; at the same time the data will automatically be available for national analysis of anonymised data.

Acknowledgement of contributors
As we have done with previous audits all contributors will be acknowledged in all papers and presentations from the audit data and biggest contributors will be offered the possibility of being co-authors.

Register to take part in the audit and access to the on-line tool
To register for the audit and be given access to the on-line tool on the ABCD website click here.

Further information
Further enquiries may be made to the ABCD nationwide audits database administrator of the project, Melissa Cull.

   Register for the semaglutide audit

Access the on-line tool

Semaglutide audit objectives

Download first visit data entry form

Download follow up visit data entry form

Nationwide exenatide audit

Nationwide liraglutide audit

Nationwide Exenatide QW audit

Further information- contact us

Main ABCD homepage

The ABCD nationwide semaglutide audit is an independent audit supported by an unrestricted grant from Novo Nordisk

Working to support high quality diabetes care in the UK